Drugs or agents that increase the activity of the enzyme CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of<unk> ; conversely, drugs that inhibit CYP1A2 activity (examples: ciprofloxacin, fluvoxamine) may reduce<unk>  clearance. Carbamazepine, a known enzyme inducer, has decreased the concentration/dose ration of<unk>  by 33% compared to<unk>  alone. Another enzyme inducer, ritonavir, has also been shown to decrease the body's exposure to<unk> , due to its induction of the enzymes CYP1A2 and uridine 5'-diphospho-glucuronosyltransferase (UGT). Probenecid increases the total exposure (area under the curve) and maximum plasma concentration of<unk> . Although<unk> 's metabolism includes the minor metabolic pathway of CYP2D6, the presence of the CYP2D6 inhibitor fluoxetine does not have a clinically significant effect on<unk> 's clearance.
Olanzapine
Aripiprazole
Risperidone
Ziprasidone
Clozapine
Sertraline
Electroconvulsive therapy
Lorpiprazole